A Precision Exit

Seroba was pleased to see its portfolio company, PrecisionBiotics, acquired by Novozymes in June 2020. The company, originally known as Alimentary Health, was a global pioneer in the study of the human microbiome and of the application of that knowledge to improvements in human health.

Partnering with the world-leading APC Microbiome Centre in Cork, Ireland, the company went on to develop precision biotics, or focused probiotics, that treat specific indications.  For instance, the well-known brand Alflorex® which has been voted 'top product' several years in a row in the Irish Pharmacy Awards, was developed by PrecisionBiotics specifically to treat IBS (Irritable Bowel Syndrome). Another of the company's products, Zenflore®, takes advantage of the gut-brain axis to provide stress-reducing benefits.

Precision Biotics Science Pic

Details of the Deal

Novozymes acquired 100% of the equity of Precisions Biotics Group (PB) for an upfront amount of €80,000,000 on a cash and debt-free basis. In addition to the upfront payment, there will be an additional performance-based earn-out. Seroba was the only institutional investor in the company.

The acquisition of PrecisionBiotics is expected to give Novozymes a stronger entry point into the €5Bn global human probiotic supplements market. Read more.

T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19

Scroll to Top